Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

TNFalpha blockade in human diseases: mechanisms and future directions.

Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, Braun J, Reed E, Singh RR.

Clin Immunol. 2008 Feb;126(2):121-36. Epub 2007 Oct 3. Review.

2.

TNFalpha blockade in human diseases: an overview of efficacy and safety.

Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR.

Clin Immunol. 2008 Jan;126(1):13-30. Epub 2007 Oct 4. Review.

3.

Biological and clinical effects of anti-TNFalpha treatment.

Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M.

Autoimmun Rev. 2007 Nov;7(1):35-41. Epub 2007 Mar 26. Review.

PMID:
17967723
4.

[Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].

Bombardieri S, Ferraccioli G, Ferri C, Galeazzi M, Lapadula G, Cerinic MM, Montecucco C, Triolo G, Trotta F, Valentini G.

Reumatismo. 2009 Apr-Jun;61 Suppl 1:1-23. Italian.

5.

TNFalpha as therapeutic target: new drugs, more applications.

Reimold AM.

Curr Drug Targets Inflamm Allergy. 2002 Dec;1(4):377-92. Review.

PMID:
14561184
6.

[Should we be afraid of the anti-TNFalpha drugs in 2008?].

Gaudin P.

Rev Med Interne. 2008 Dec;29(12):971-4. doi: 10.1016/j.revmed.2008.04.022. Epub 2008 Jun 20. French. No abstract available.

PMID:
18571291
7.

Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.

Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1):31-8. Epub 2012 Mar 6.

PMID:
22153557
8.

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.

PMID:
19224750
9.

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.

Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T.

Inflamm Bowel Dis. 2007 Nov;13(11):1323-32.

PMID:
17636564
10.

Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.

Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M.

Arthritis Rheum. 2008 May;58(5):1248-57. doi: 10.1002/art.23447.

11.

[Efficacy and security of tumor necrosis factor antagonists in the treatment of rheumatoid arthritis].

Pérez Pampín E, Gómez-Reino Carnota JJ.

Med Clin (Barc). 2008 Feb 16;130(5):179-87. Review. Spanish.

PMID:
18341834
12.

[Anti-TNFα therapy in ankylosing spondylitis: symptom control and structural damage modification].

Andreu JL, Otón T, Sanz J.

Reumatol Clin. 2011 Jan-Feb;7(1):51-5. doi: 10.1016/j.reuma.2009.03.007. Epub 2010 Apr 10. Review. Spanish.

13.

[Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].

Lanfant-Weybel K, Lequerré T, Vittecoq O.

Presse Med. 2009 May;38(5):774-87. doi: 10.1016/j.lpm.2009.02.003. Epub 2009 Mar 26. French.

PMID:
19327945
14.

Differentiating the efficacy of tumor necrosis factor inhibitors.

Haraoui B.

J Rheumatol Suppl. 2005 Mar;74:3-7. Review.

PMID:
15742457
15.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators.

Lancet. 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26. Erratum in: Lancet. 2009 Oct 24;374(9699):1422.

PMID:
19560810
16.

[New drugs and treatment strategies for rheumatoid arthritis].

Fantini F.

Recenti Prog Med. 2003 Sep;94(9):361-79. Review. Italian.

PMID:
12942798
17.

Which TNF inhibitor for rheumatoid arthritis?

[No authors listed]

Med Lett Drugs Ther. 2010 May 17;52(1338):38-9. No abstract available.

PMID:
20467356
18.

[Value of anti-TNF-alpha molecules in inflammatory and infectious diseases].

Fautrel B, Cherin P.

Rev Med Interne. 2000 Oct;21(10):872-88. Review. French.

PMID:
11075396
19.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Collamer AN, Battafarano DF.

Semin Arthritis Rheum. 2010 Dec;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003. Epub 2010 Jun 26. Review.

PMID:
20580412
20.

High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.

Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, Montecucco C.

Ann Rheum Dis. 2007 Mar;66(3):302-7. Epub 2006 Nov 1.

Supplemental Content

Support Center